{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T11:11:21Z","timestamp":1648897881400},"reference-count":18,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycythemia vera (PV) is an acquired myeloproliferative disorder with primary expansion of the red cell mass leading to an increased risk of thrombosis and less frequently to myelofibrosis and secondary acute leukemia. Standard therapies include cytoreduction with either phlebotomy or chemotherapeutic agents and antithrombotic drugs. Because long-term exposure to cytotoxic chemotherapy may increase the risk of acute transformation, new therapeutic options are needed. Tipifarnib is a nonpeptidomimetic inhibitor of farnesyl transferase that was developed as a potential inhibitor of RAS signaling. In the present study we report that tipifarnib used at pharmacologically achievable concentrations strongly inhibits the erythroid burst-forming unit (BFU-E) autonomous growth that characterizes patients with PV. Moreover, at low tipifarnib concentrations (0.15 \u03bcM), the inhibitory effect was preferentially observed in PV BFU-E progenitors and not in normal BFU-E progenitors and was not rescued by erythropoietin (EPO). Thus tipifarnib may specifically target PV stem cells and may be of clinical interest in the treatment of patients with PV.<\/jats:p>","DOI":"10.1182\/blood-2004-07-2949","type":"journal-article","created":{"date-parts":[[2005,1,5]],"date-time":"2005-01-05T02:33:11Z","timestamp":1104892391000},"page":"3743-3745","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells"],"prefix":"10.1182","volume":"105","author":[{"given":"Je\u0301ro\u0302me","family":"Larghero","sequence":"first","affiliation":[{"name":"From the Laboratoire de Biologie Cellulaire He\u0301matopoi\u0308e\u0301tique, Institut d'He\u0301matologie and Service de Me\u0301decine Nucle\u0301aire, Ho\u0302pital Saint-Louis, Paris, France; Service Clinique des Maladies du Sang, Ho\u0302pital Saint-Louis, Paris, France; and Unite\u0301 de The\u0301rapie Cellulaire, Ho\u0302pital Saint-Louis, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Gervais","sequence":"additional","affiliation":[{"name":"From the Laboratoire de Biologie Cellulaire He\u0301matopoi\u0308e\u0301tique, Institut d'He\u0301matologie and Service de Me\u0301decine Nucle\u0301aire, Ho\u0302pital Saint-Louis, Paris, France; Service Clinique des Maladies du Sang, Ho\u0302pital Saint-Louis, Paris, France; and Unite\u0301 de The\u0301rapie Cellulaire, Ho\u0302pital Saint-Louis, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Cassinat","sequence":"additional","affiliation":[{"name":"From the Laboratoire de Biologie Cellulaire He\u0301matopoi\u0308e\u0301tique, Institut d'He\u0301matologie and Service de Me\u0301decine Nucle\u0301aire, Ho\u0302pital Saint-Louis, Paris, France; Service Clinique des Maladies du Sang, Ho\u0302pital Saint-Louis, Paris, France; and Unite\u0301 de The\u0301rapie Cellulaire, Ho\u0302pital Saint-Louis, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Didier","family":"Rain","sequence":"additional","affiliation":[{"name":"From the Laboratoire de Biologie Cellulaire He\u0301matopoi\u0308e\u0301tique, Institut d'He\u0301matologie and Service de Me\u0301decine Nucle\u0301aire, Ho\u0302pital Saint-Louis, Paris, France; Service Clinique des Maladies du Sang, Ho\u0302pital Saint-Louis, Paris, France; and Unite\u0301 de The\u0301rapie Cellulaire, Ho\u0302pital Saint-Louis, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-He\u0301le\u0300ne","family":"Schlageter","sequence":"additional","affiliation":[{"name":"From the Laboratoire de Biologie Cellulaire He\u0301matopoi\u0308e\u0301tique, Institut d'He\u0301matologie and Service de Me\u0301decine Nucle\u0301aire, Ho\u0302pital Saint-Louis, Paris, France; Service Clinique des Maladies du Sang, Ho\u0302pital Saint-Louis, Paris, France; and Unite\u0301 de The\u0301rapie Cellulaire, Ho\u0302pital Saint-Louis, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose Ann","family":"Padua","sequence":"additional","affiliation":[{"name":"From the Laboratoire de Biologie Cellulaire He\u0301matopoi\u0308e\u0301tique, Institut d'He\u0301matologie and Service de Me\u0301decine Nucle\u0301aire, Ho\u0302pital Saint-Louis, Paris, France; Service Clinique des Maladies du Sang, Ho\u0302pital Saint-Louis, Paris, France; and Unite\u0301 de The\u0301rapie Cellulaire, Ho\u0302pital Saint-Louis, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Chomienne","sequence":"additional","affiliation":[{"name":"From the Laboratoire de Biologie Cellulaire He\u0301matopoi\u0308e\u0301tique, Institut d'He\u0301matologie and Service de Me\u0301decine Nucle\u0301aire, Ho\u0302pital Saint-Louis, Paris, France; Service Clinique des Maladies du Sang, Ho\u0302pital Saint-Louis, Paris, France; and Unite\u0301 de The\u0301rapie Cellulaire, Ho\u0302pital Saint-Louis, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[{"name":"From the Laboratoire de Biologie Cellulaire He\u0301matopoi\u0308e\u0301tique, Institut d'He\u0301matologie and Service de Me\u0301decine Nucle\u0301aire, Ho\u0302pital Saint-Louis, Paris, France; Service Clinique des Maladies du Sang, Ho\u0302pital Saint-Louis, Paris, France; and Unite\u0301 de The\u0301rapie Cellulaire, Ho\u0302pital Saint-Louis, Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021222435393300_REF1","doi-asserted-by":"crossref","unstructured":"Green AR. Pathogenesis of polycythaemia vera. Lancet. 1996:347: 844-845.","DOI":"10.1016\/S0140-6736(96)91338-0"},{"key":"2020021222435393300_REF2","doi-asserted-by":"crossref","unstructured":"Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991:85: 124-127.","DOI":"10.1159\/000204873"},{"key":"2020021222435393300_REF3","doi-asserted-by":"crossref","unstructured":"Janssen JW, Steenvoorden AC, Lyons J, et al. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci U S A. 1987:84: 9228-9232.","DOI":"10.1073\/pnas.84.24.9228"},{"key":"2020021222435393300_","unstructured":"Sakai H, Karasawa M, Okamoto K, et al. Leukemic transformation in three patients with polycythemia vera: analysis of the clinicopathological features and N-ras gene mutation. J Med. 1996:27: 183-191."},{"key":"2020021222435393300_REF5","doi-asserted-by":"crossref","unstructured":"Tsurumi S, Nakamura Y, Maki K, et al. N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am J Hematol. 2002:71: 131-133.","DOI":"10.1002\/ajh.10188"},{"key":"2020021222435393300_REF6","unstructured":"Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 1995:55: 5310-5314."},{"key":"2020021222435393300_REF7","doi-asserted-by":"crossref","unstructured":"Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 2000:19: 6584-6593.","DOI":"10.1038\/sj.onc.1204146"},{"key":"2020021222435393300_REF8","doi-asserted-by":"crossref","unstructured":"Vervenne WL, Bos CL, Rens LS, Peppelenbosch MP, Richel DJ. Farnesyl protein transferase inhibition interferes with activation of MAP kinase family members in human peripheral blood monocytes. Mol Med. 2002:8: 857-862.","DOI":"10.1007\/BF03402091"},{"key":"2020021222435393300_REF9","unstructured":"Pellagatti A, Vetrie D, Cordelia F, et al. Gene expression profiling in polycythemia vera using cDNA microarray technology. Cancer Res. 2003:63: 3940-3944."},{"key":"2020021222435393300_REF10","unstructured":"End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001:61: 131-137."},{"key":"2020021222435393300_REF11","unstructured":"Smith V, Rowlands MG, Barrie E, Workman P, Kelland LR. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res. 2002:8: 2002-2009."},{"key":"2020021222435393300_REF12","doi-asserted-by":"crossref","unstructured":"Lancet JE, Rosenblatt JD, Karp JE. Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias. Semin Hematol. 2002:39: 26-30.","DOI":"10.1053\/shem.2002.35985"},{"key":"2020021222435393300_","doi-asserted-by":"crossref","unstructured":"Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibtor, R115777, in advanced breast cancer. J Clin Oncol. 2003:21: 2492-2499.","DOI":"10.1200\/JCO.2003.10.064"},{"key":"2020021222435393300_","unstructured":"Adjei AA, Croghan GA, Erlichman C, et al. A phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2003:9: 2520-2526."},{"key":"2020021222435393300_REF15","doi-asserted-by":"crossref","unstructured":"Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic\/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004:103: 3271-3277.","DOI":"10.1182\/blood-2003-08-2764"},{"key":"2020021222435393300_REF16","doi-asserted-by":"crossref","unstructured":"Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000:18: 927-941.","DOI":"10.1200\/JCO.2000.18.4.927"},{"key":"2020021222435393300_REF17","doi-asserted-by":"crossref","unstructured":"Oehler L, Jaeger E, Eser A, et al. Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. Blood. 2003:102: 2240-2242.","DOI":"10.1182\/blood-2003-03-0676"},{"key":"2020021222435393300_REF18","doi-asserted-by":"crossref","unstructured":"Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001:97: 3361-3369.","DOI":"10.1182\/blood.V97.11.3361"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/9\/3743\/1710073\/zh800905003743.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/9\/3743\/1710073\/zh800905003743.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T06:19:09Z","timestamp":1586067549000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/9\/3743\/21280\/Farnesyltransferase-inhibitor-tipifarnib-R115777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,1]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-07-2949","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,1]]}}}